Kelzy (Dienogest, Ethinylestradiol | Lactose)

The ethinylestradiol component provides estrogen activity while dienogest supplies a progestogenic effect. Together they suppress the mid‑cycle surge of luteinising hormone, preventing ovulation. They also thicken cervical mucus and alter the endometrial lining, creating an environment that is hostile to sperm penetration and implantation.

The specific dose and regimen of Kelzy must be prescribed by a qualified health‑care provider. Typically, combined oral contraceptives are taken once daily for 21 days followed by a hormone‑free interval, but the exact tablet strength and schedule are determined by the prescriber based on individual patient factors.

Kelzy is intended for use only when pregnancy is not present. If a woman becomes pregnant while taking the product, she should discontinue it and seek medical advice. The safety of combined oral contraceptives during breastfeeding is not established; clinicians usually advise caution and may recommend alternative contraception.

To place an order, submit an enquiry on the Kelzy product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kelzy contains dienogest, a progestin with a lower androgenic profile, combined with ethinylestradiol, which may offer a favorable bleeding pattern and reduced risk of certain side effects compared with older formulations that use levonorgestrel. However, efficacy and safety are comparable across approved combined oral contraceptives when taken as directed.

Kelzy tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the medication out of reach of children and do not use tablets that have changed appearance or are past their expiry date.

Kelzy is taken orally, usually once each day at the same time, with or without food. The standard regimen involves a 21‑day active tablet sequence followed by a 7‑day pill‑free interval, during which withdrawal bleeding occurs. Patients should follow the schedule prescribed by their health‑care provider.

The most serious risks include venous thromboembolism, arterial thrombosis, myocardial infarction, stroke, and severe hypertension, especially in women who smoke, are over 35, or have underlying cardiovascular disease. Rare cases of liver tumors and severe allergic reactions have also been reported. Immediate medical attention is required if symptoms such as chest pain, shortness of breath, or severe abdominal pain occur.

Kelzy is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over the age of 35 and by individuals taking medications that strongly induce hepatic enzymes, which can reduce contraceptive effectiveness. A health‑care professional should assess suitability before prescribing.